Azapropazone in the treatment of ankylosing spondylitis: a controlled clinical trial.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002490:Central Nervous System / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002986:Clinical Trials as Topic; D004064:Digestive System / Q000187:drug effects; D004123:Dimethylamines / Q000009:adverse effects / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008314:Malonates / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010919:Placebos; D011379:Prognosis; D011859:Radiography; D012137:Respiratory System / Q000187:drug effects; D012399:Rotation; D013131:Spine / Q000503:physiopathology; D013167:Spondylitis, Ankylosing / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D004123:Dimethylamines; D008314:Malonates; D010919:Placebos; D014227:Triazines